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ABSTRACT  
Background: Inflammatory Bowel Disease (IBD) imposes a heavy psychosocial burden, with many patients 
reporting anxiety, depression and distress. In diseases such as diabetes, disease-specific distress is 
associated with concordance with treatments and disease control. IBD-distress, distinct from anxiety and 
depression, is evident in people with IBD. We aimed to develop a questionnaire for assessing IBD disease-
specific distress, validate this against a gold standard distress measure for diabetes, and demonstrate 
difference between anxiety, depression, and distress.   
Methods: The 94 item IBD-Distress Scale (IBD-DS), was developed through secondary analysis of three 
qualitative data sets from previous IBD studies. Items were then refined through cognitive interviews in two 
stages (n=15; n=3). Three supplementary unscored questions were added to enable patients to identify their 
overall level of distress, their perceived level of disease activity, and their three most distressing issues. 
Subsequently the 55 item IBD-Distress scale was subjected to test-retest.  275 people received the test draft 
IBD-DS, 168 responded (60.4%). Of these, 136 (82%) returned the retest draft IBD-DS three weeks later. 
Following analysis, further item reduction was informed by response rates, kappa values, and correlation 
coefficients, and test-retest was repeated. 154 people received the test final 28 item IBD-DS, 123 people 
responded (58.8%). Of these, 95 (77%) returned the retest final IBD-DS.  
Results: The 94 items were reduced to 28 items. Good intra-class correlation (ICC) was found between test-
retest scores on 72 complete data sets with unchanged disease status (ICC 0.92; 95% CI, 0.88, 0.95). 
Cronbach’s alpha was 0.95 indicating excellent internal consistency. Factor analysis indicated scoring the 
items as a single domain (score range 0-168).  
Conclusion: The final IBD-DS performs well and offers a tool for assessing IBD disease-specific distress. 
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INTRODUCTION 
Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), can have 
burdensome psychosocial consequences for those with the condition 1 including distress related to 
symptoms 2. Distress may be understood as an ‘emotional anguish or suffering’ 3, or as ‘a non-specific, 
biological or emotional response to a demand or stressor that is harmful to the individual’ 4.   
 
Disease-related distress has been identified and researched extensively in other chronic conditions 
including diabetes 5-9, asthma 10, 11, cancer 12-14 and multiple sclerosis 15. Earlier work from this study team 
has identified and reported the phenomenon in people with IBD 16. Studies reporting ‘psychological distress’ 
in IBD have often measured only anxiety and depression 17, 18, although evidence from diabetes 19, cancer 
13, and multiple sclerosis 15 demonstrates that whilst it may be related, disease-related distress is distinct 
from anxiety and depression 6. However, unlike anxiety and depression, disease specific distress is not a 
diagnosable condition in the DSM Manual of Psychiatric Diagnoses 20. Disease-specific distress is a 
spectrum of emotional experience relating to the disease being experienced by the person 21. In IBD-
distress we define this as the person‘s experience of feeling overwhelmed by the demands of living with 
and managing their condition. We hypothesize its distinctiveness from anxiety and depression in that it is 
uniquely focused in emotional response to disease experience and not generalized to other psychological 
morbidities. In diabetes, an analysis of the clinical notes of 40 people with elevated distress diabetes 
estimated that 30% had an additional underlying co-morbid anxiety and/or depression with the majority 
70% demonstrating no signs of psychological co-morbidity but  experiencing disease specific distress alone 
22. Disease-specific distress could therefore be defined as ‘an emotional response to the burden of chronic 
illness symptoms which may share symptoms of anxiety and depression, but is not diagnosed as such and 
is attributable only to the emotional response to disease experience’.       
 
Cut offs for elevated distress have been established in diabetes 23-25. Elevated diabetes distress is 
associated with higher blood glucose levels and fewer self-care behaviours such as medication 
concordance and disease monitoring 19. Addressing diabetes distress improves clinical outcomes in 
interventional studies in type 1 and type 2 diabetes and in adolescents 8, 9 and this may be important for 
IBD as well, where the problems of concordance with oral medications are also recognised 26, 27. The higher 
prevalence of symptoms of anxiety and depression in people with IBD, when compared to the general 
population, is well established 28-30 yet the presence and impact of IBD-distress remains under-explored. 
There are no tools to assess IBD-distress in IBD patients, and it is likely to be poorly identified and so 
support may not be offered. An assessment tool for IBD distress may evidence the need for additional 
support, and in the longer term has the potential to improve patient quality of life and self-management in 
IBD. 
 
In preliminary work, we collaborated with our Patient and Public Involvement (PPI) group to identify the 
presence and impact of IBD-related distress, through secondary analysis of existing qualitative data from 
our previous studies addressing fatigue, stigma, and incontinence in IBD 31-34. By comparing the findings 
with the domains of the Diabetes Distress Scale (4), we identified that people with IBD have many similar, 
but some unique disease-related sources of distress. In previously published work we confirmed findings 
via a patient focus group (n=8) and a clinician Delphi study (n=20), resulting in 94 items that could be used 
to assess IBD distress. These were contained in five distinct domains of emotional, healthcare-related, 
interpersonal / social, treatment-related and symptom-related distress 16. This paper builds on our earlier 
work and reports refinement of the 94 item IBD-DS into the final 28 item IBD-DS; it also reports comparison 
with a gold standard scale for diabetes distress 35 and with a scale for symptoms of anxiety and depression 
36, and determines the new scale’s face, content and construct validity, and reliability  via test-retest 37 in 
people living with IBD.  
 
MATERIALS AND METHODS  
Following preliminary work reported elsewhere 16, we conducted a three-phase study guided by 
recommended procedures for development of a patient reported outcome measure (PROM) 38. We aimed 
to:  Phase 1: use cognitive interviews to refine the initial 94 item IBD-Distress Scale (IBD-DS), reducing the 
number of items; Phase 2: use scale validation methods 38 to undertake psychometric validation of the draft 
IBD-DS via test-retest, and statistical analysis to determine the possibility of further item reduction; Phase 
3: test-retest and psychometric validation of the reduced final IBD-DS with newly-recruited participants.  
 
 
Study sample  
Phase 1 and 2 participants were recruited from IBD clinics at two large UK university hospitals and invited 
to participate in both phases. Inclusion criteria were: confirmed diagnosis of IBD by endoscopy, and aged 
over 18 years. Four hundred and twenty three consecutive eligible clinic attenders were invited to 
participate and 338 (80%) agreed to participate. Eighteen of 41 volunteers for Phase 1 were purposefully 
selected for cognitive interviews to represent a broad spread of gender, age, diagnosis and geographic 
location. 297 patients agreed to participate in Phase 2.  
Phase 3 participants were recruited from members of a United Kingdom IBD charity via social media 
platforms and website advertising, with 209 registering an interest and 123 participating.   
  
Sample size 
Phase 1: It is not possible to calculate sample size for cognitive interviewing, since the number of interview 
rounds needed to finalize adjustments to the draft PROM cannot be pre-empted. Evidence 39, 40 and our 
previous experience 32, 41 indicates that three to four rounds, with approximately five interviews per round, is 
usually sufficient. We continue to interview from our pool of 41 potential participants until the Phase 1 aim 
of developing a coherent and understandable draft questionnaire was achieved.  
 
Phases 2 and 3:  Sample size for a new questionnaire is impossible to determine a priori as there is no 
data on the width of confidence intervals. A minimum sample size of 30 – 40 has been recommended 40, 
increasing with the number of items to be tested 42, but an accepted ‘rule of thumb’ indicates 10 participants 
per item although this has never been verified 43, 44.  
 
 
Data collection tools 
Demographic data (age, gender and IBD diagnosis) were collected from all participants. In Phases 2 and 3, 
disease activity was self-assessed by participants using the Crohn’s Disease Activity (Harvey Bradshaw) 
Index (HBI) 45 for those with CD, and the Simple Clinical Colitis Activity Index (SCCAI) 46 for those with UC. 
We have successfully collected remote patient completion of the HBI and SCCAI in previous studies 32, 41. A 
disease activity score of 4 or below indicated remission, whilst a score of 5 or above indicated relapse.   
 
To enable comparison with distress in other conditions, and with anxiety and depression, participants also 
completed the modified Diabetes Distress Score 35 in Phase 2, and the Hospital Anxiety and Depression 
Score 36 in Phases 2 and 3.  
 
The Diabetes Distress Scale (DDS) 35 is a self-administered 17- item validated tool with a score range of 
17-102, for detecting emotional distress in patients with diabetes. For this study, we replaced the word 
‘diabetes’ with the acronym ‘IBD’ but retained all other features of the scale. Our preliminary work 16 
identified some similarities between DDS domains and draft IBD-DS items, thus providing the support for 
this rationale.   
 
The DDS comprises four sub-scales: emotional burden (5 items), physician-related distress (4 items), 
regimen-related distress (5 items), and interpersonal distress (3 items).   Responses to each item are rated 
on a 6-point frequency scale. A mean score of three or more (moderate distress) indicates elevated 
distress likely to impact on glycaemic control and self-care behaviours in people with diabetes, warranting 
clinical attention 35. The DDS was chosen to enable comparison of IBD distress with another validated 
disease-related distress tool.  
   
The Hospital Anxiety and Depression score (HADS) 36 is a 14-item self-administered validated tool 
comprised of two subscales (Anxiety and Depression) each with a score ranging from 0 – 21. Scores of 0-7 
indicate normal levels of anxiety and depression; 8 -10 indicates borderline abnormal anxiety and 
depression; 11-14 indicates moderate anxiety and depression and 15-21 suggests severe levels of anxiety 
and depression. HADS was selected because it is a recognized generic tool for assessing anxiety and 
depression in people with physical disease and was used in this study with permission and under license 
from GL Assessments.  
 
Patient and Public Involvement 
A patient and public involvement (PPI) team of two men and two women with IBD was recruited from the 
membership of the funding charity, and from a UK IBD charity. The team had significant involvement in the 
preliminary work to identify distress in IBD 16. In this study, they participated in designing the layout of the 
new IBD Distress Scale, in the item reduction process after the Phase 1 cognitive interviews and in 
planning dissemination activities. PPI involvement in research is widely encouraged and potential benefits 
of the role of PPI in PROM development have been reported 47. These benefits reflect those seen in clinical 
trials and other engagement projects – including ‘increasing the quality and quantity of patient relevant 
priorities and outcomes’ 48.   
 
Data collection 
An overview of the full development and testing process is provided in Fig.1.  
Phase 1: IBD-DS item generation and item reduction (Fig.1 Box A) 
Development of patient-reported measures usually begins by interviewing people with the condition of 
interest to identify potential content 38. Our preliminary work 16, which provided 94 items for the first draft of 
the new Inflammatory Bowel Disease Distress Scale (IBD-DS), replaced this stage.  
 
Establishing face and content validity (Fig.1 Box B) 
Addressing face validity (the ease with which the completing person can understand each question) and 
content validity (the relevance of questionnaire content) are the next stages in developing a new 
questionnaire 38. During an initial three rounds of cognitive interviews (n=15), face and content validity of 
the 94-item draft IBD-DS were explored. Cognitive interviews are used to detect problems participants may 
have in understanding / interpreting the questions, and in being able to give the response they wish to give 
49. Attention is also paid to grammar, layout, ease of use and item completion rate, using ‘think aloud’ and 
verbal probing techniques 50. Cognitive interviews help to identify ambiguous or misleading questions, and 
whether the response and scoring options are appropriate. These initial 15 interviews were digitally audio-
recorded, and transcribed.  Between interview rounds, revisions were made to the developing IBD-DS, 
using simple thematic analysis of transcripts and notes, and discussion between three of the authors (LD, 
CN, SW).  
 
Initial item reduction (Fig. 1 Box C) 
Over three interview rounds, the draft IBD-DS was reduced from 94 to 88 items and wording was refined. 
The study team, including PPI representatives, conducted a simple analysis of the spread of responses 
from each participant. Twenty-four questions were deleted and 15 were combined to create six new 
questions. In response to interview participants’ comments, the rating scale was amended from 0–10, to 0-
6. Three supplementary unscored questions were added: a 0 – 6 scale for current overall level of distress 
(0 = not distressed; 6 = highly distressed); a scale for reporting perceived current level of disease activity 
(in remission; mild flare; moderate flare; severe flare); and a free-text item for prioritizing their top three 
current causes of distress.  
 
The 55 item draft IBD-DS was then tested via three further cognitive interviews (Fig. 1 Box D). No further 
substantive changes were required, confirming a 55- item draft IBD-DS (each item scored 0-6, score range 
0-330), plus three supplementary unscored questions.  
 
Phase 2 
Determining construct validity and reproducibility (Fig.1 Box E)  
Our aim was to determine how well the 55 item draft IBD-DS performed by assessing response rates to 
individual questions; sensitivity (identifies respondents who are distressed as different from those who are 
not); and test-retest reliability (questionnaire performs similarly on more than one occasion when the 
underlying condition is unchanged). A further aim was to determine whether the draft IBD-DS correlated 
with the validated Diabetes Distress Scale (DDS) (7) and with the HADs.  
 
Participants completed paper copies of the draft IBD-DS on two occasions (test and re-test), approximately 
three to four weeks apart. They indicated with a Yes/No response whether a question was relevant to them, 
completing a distress score (0-6) for that question if they answered ‘yes’. A ‘no’ answer scored zero. 
Participants also completed three supplementary questions. On the first occasion (test) participants also 
completed a study-specific demographic details form, the HADS 36, and the modified DDS; the HBI 45, or 
the SCCAI 46 were completed at both test and retest. One email was sent to remind participants to return 
their documents by post. Microsoft Excel (2010) and Stata (Version 13.2) were used to manage and 
analyze data. After data analysis (see results section), the draft IBD-DS was reduced to 28 items (Fig.1 
Boxes F & G). 
 
Phase 3 
Confirming construct validity and reliability (reproducibility) (Fig.1 Boxes H & I) 
The test-retest phase was repeated with the 28-item questionnaire and a new cohort of community-based 
participants using identical processes as described above for Phase 2. As the purpose was to confirm the 
reproducibility, further associations with the DDS 35 were not tested.  
 
Statistical methods 
Data from the various scores were summarized using mean and standard deviation (normal distribution), 
and median and inter-quartile range (positively skewed distribution). Analyses of the association between 
the IBD-DS scale and HADS 36 were performed using Pearson’s correlation, and was restricted to the 
Phase 2 ‘test’ data only.  
 
The internal consistency of the items making up the IBD-DS scale were assessed using Cronbach’s alpha. 
A high value (close to +1) would suggest good internal consistency of the score.   
 
Two sets of repeatability analyses were performed on the test and retest data in Phase 3. Patients whose 
disease status changed from active to inactive (or vice versa) between the two sets of measurements were 
excluded. The first analysis examined the agreement in the actual measured scores using the Bland-
Altman limits of agreement method. This method quantifies the size of differences between pairs of values 
that are likely to occur.  
 
A second repeatability analysis examined agreement using the intra-class correlation (ICC) method. This 
method divides the total variability in the IBD-DS measurements into two sources: the variation between 
patients, and the variation in repeat measurements of the same patient. The ICC is the proportion of total 
variation that is between patients. If there is good agreement between patients, there should be little 
variability between repeat measurements of the same patient, and thus most variability should be between 
patients, giving ICC values close to 1.  
 
A final analysis examined patterns between individual items within the scale using a factor analysis. The 
importance of the factors identified was determined by the size of the eigenvalue associated with each 
factor. Factor loadings were given a Varimax rotation to aid interpretation of results. Items with factor 
loadings of 0.5 or higher were deemed to be associated with a particular factor.   
 
Ethical considerations   
Ethical approval for this study was granted by the NRES Committee South West - Cornwall & Plymouth 
[REC Reference 14/SW/0132] (Phases 1 and 2), and by the Research Ethics Committee at King’s College 
London [REC reference LRS-15/16-3674] (Phase 3). Written informed consent was collected from 
participants immediately prior to the individual cognitive interviews in Phase 1; consent to participate in 
Phases 2 and 3 was implied by return of completed questionnaires.  
RESULTS 
Demographic details of all study participants are provided in Table 1.  
 
Phases 1 and 2 
Of the 297 people who initially volunteered for Phases 1 and 2, 24 could not take part (n=18 could not be 
contacted, n=4 had changed their minds about taking part, and n=2 had died). Fifteen people participated in 
cognitive interviews in Phase 1, and following initial item reduction, three further cognitive interviews were 
conducted to verify the changes to the questionnaire. 273 people received the 55-item test draft IBD-DS in 
Phase 2. 168 (61.5%) participants responded. Of these, 136 (81%) returned the retest draft IBD-DS.  
 
 
Statistical analysis using Spearman’s rank correlation indicated a positive correlation between the IBD-DS 
and the modified DDS (CC 0.85, p<0.001), and between the IBD-DS and the HADS (Anxiety: CC 0.64, 
p<0.001; Depression: CC 0.54, p<0.001) [Table 2]. All correlations were positive, suggesting that higher 
IBD-DS values were associated with higher values on all other measures. Scatterplots demonstrating the 
association between the IBD-DS, the HADS and the DDS are available online [Online DSF 1].      
 
Secondary item reduction 
Further statistical analysis using weighted kappa, calculation of mean scores and percentage of non-zero 
scores, and observation of response rates was conducted. Principle Component Factor Analysis was not 
used at this stage because there was no pre-defined grouping of the items, making even a partial 
confirmatory factor analysis difficult to perform.  
Following team discussion, a further 27 items were removed resulting in a 28-item final IBD-DS (each item 
scored 0-6, score range 0-168), plus three supplementary unscored questions. This version was circulated 
to a sub-sample of Phase 2 participants who had returned their test-retest questionnaires promptly (n=20). 
Twelve responded, endorsing the changes.   
 
Phase 3 
Of the 209 people who volunteered for Phase 3 and received the 28-item test final IBD-DS, 123 (58.8%) 
responded. Of these 95 (77%) returned the retest final IBD-DS.  
 
Data summaries and correlation between scores 
Test and retest data for Phase 3 are summarised in Table 3. IBD-DS scores were approximately normally 
distributed suggesting an absence of a floor or ceiling effect.  
 
Construct validity 
Examination of the association between the IBD-DS score and the HADS 36, HBI 45 and SCCAI 46 revealed 
that higher IBD-DS values were associated with higher values on all other measures. The highest 
correlation (r = 0.77) was with the stand-alone self-reported distress item of the IBD-DS [Table 2], although 
there were correlations with both HADS scores (anxiety, r = 0.68; depression, r = 0.62) as well (all 
p<0.001).  
 
Internal consistency 
The calculated value for Cronbach’s alpha was 0.95, and for Guttman’s Lambda 2 statistic was 0.94. Both 
suggest that the final IBD-DS scale has a high degree of internal consistency.  
 
Reproducibility and stability over time (repeatability) 
There were 95 participants with both test and retest data. Of these, 19 experienced a change in their 
disease activity (remission to relapse, or vice versa) between test and retest and three had significant 
missing data. These participants were excluded from the test-retest analysis. Two analyses were 
performed on the remaining 72 data sets. Analysis using the intra-class correlation (ICC) calculated an ICC 
value of 0.92 (95% CI, 0.88, 0.95) indicating fairly good to excellent agreement between test and retest 
values. Bland-Altman analysis suggested a mean difference between time-points of 0.5, with a range of -
29.4 to +30.4 between the 95% limits. Thus the score could vary by +/- 30 units between occasions. 
Clinical judgement is required as to whether this is an acceptable amount of variation.  
 
Factor analysis 
Factor analysis identified four factors, with importance indicated by eigenvalue. Factor 1 (eigenvalue 13.2) 
was much larger than the remaining factors (Factor 2: 1.9; Factor 3: 1.3; Factor 4: 1.2), and explained 
almost half of all variation in the data. On the basis that there is no statistical suggestion that it is logical to 
combine the remaining factors, a single domain with an overall score (range 0-168, plus three 
supplementary unscored questions) is recommended. The final version of the IBD-DS is provided as 
supplementary online material [Online DSF 2].  
 
DISCUSSION 
The IBD-DS demonstrates good content validity, internal consistency, construct validity, moderate reliability 
(agreement and reproducibility), and absence of floor and ceiling effects (≤ 15% of respondents achieved 
the highest or lowest possible scores). The remaining criteria (responsiveness to change and 
interpretability) will be addressed in full psychometric validation during future intervention studies. A 
particular strength of the new scale is the robust developmental process which has included our PPI team 
throughout, ensuring that the IBD-DS reflects the needs and concerns of patients with IBD 48. The scale can 
be printed on a single sheet (two sides) of paper (A4), and scoring and identification of the patient’s priority 
issues is rapid.  
There are some similarities between items of the IBD-DS and those of the DDS. This is unsurprising given 
the key role of the DDS in the early development of items for the IBD-DS 16. The DDS domains (emotional 
burden, physician-related distress, regimen-related distress, and interpersonal distress) were not identified 
as separate domains in the IBD-DS, yet the final items of IBD-DS are similar to the DDS in terms of 
treatment/regimen distress and in emotional/psychosocial burden. Differences appear to relate to the role 
of others in each disease. In diabetes, over-monitoring and criticism by family members 51 can cause 
distress and are contained within the interpersonal distress items of the DDS as a result of the surveillance 
role close family and friends feel the need to perform. In IBD it is the perceived burden of the disease on 
family that causes the distress. Both are socially constructed distresses but with different roots.  Diabetes 
does not appear to limit peoples’ life choices in the way that IBD does. This may relate to a perceptions of 
good public awareness of diabetes in contrast to IBD. 
Inflammatory bowel disease is manifested in many complex symptoms which have a negative impact on 
patients’ quality of life (QoL). The IBD-DS is an addition to a range of disease-specific patient-reported 
outcome measures (PROMs) which assess, for example, and QoL 52, fatigue 41, continence 32, and 
perceptions of disease control 53, in people with IBD. The use of PROMs in all areas of clinical research and 
practice is increasingly recognised as being the best indicator of the impact of clinical interventions, whilst 
also keeping the patient perspective at the heart of research and clinical care 54.  Data from disease-
specific PROMS enable monitoring of IBD treatment and interventions, whilst data from generic health-
related quality of life (HRQoL) measures enable comparison with other chronic conditions 55. Generic and 
disease-specific measures may also assess different but equally important aspects of disease impact, and 
can therefore be used together to gain a composite view 56. Test data analysis shows IBD-DS scores to 
have a significant positive correlation (all p<0.001) with existing validated tools. Indications are that the new 
IBD-DS detects and measures disease-related distress in IBD, as the DDS 35 does for diabetes 6.  
 
The significant correlation with both HADS scores is indicative of the inter-relationship often co-exists in 
chronic illnesses 12, 13. This symptom overlap is potentially considerable and is complex for patients and 
clinicians to unravel what is physical disease (IBD), psychiatric diagnosis (clinical depression) psychological 
morbidity (depressive symptoms) and emotional consequences of living with physical disease (IBD-
distress). Disease specific distress is conceptually different from other commonly assessed patient reported 
outcomes such as quality of life and depression, because it derives purely from the disease itself and not 
from any extraneous factors. Different types of intervention may be required to manage it 6. The IBD-DS 
addresses distress associated with the unique features of living with this specific disease, rather than the 
more generic aspects of emotional wellbeing addressed in the HADS. Previous identification of IBD-related 
concerns 57-59 identify bothersome issues amongst IBD populations but do not assess the impact of these 
issues on the individual.  
 
Establishing cut-off points 
Further work is needed to establish cut-off points. The normal distribution of scores suggests that there is a 
range of experience of distress amongst IBD patients. Elevated diabetes distress across diabetes 
populations are around 22% 5 and it is therefore to be expected that many people with IBD will not 
experience levels of distress that impact their self-management. Cut-off points, denoting no, mild, moderate 
and severe distress, may emerge from future studies. Data from a larger, more generalized study 
population would establish clinically concerning levels of distress for IBD which might inform scoring by 
determining the threshold at which distress levels would warrant clinical attention. A single summative 
score is indicated by statistical analysis which did not support retaining separate domains.     
 
Clinical usefulness 
Disease-related distress impacts on clinical outcomes and self-care behaviours in numerous other long-
term conditions 3, 12, 13. A recent European-wide survey of people with IBD reports the immense impact the 
illness has, and that patients do not always have the opportunity to raise their concerns during clinical 
consultations 60. The availability of the IBD-DS to assess disease-related distress offers patients a means of 
indicating and prioritising their concerns, and gives clinicians a guide to understand how best to support the 
patient. Assessing distress levels routinely in IBD consultations may inform clinical decision-making by 
providing insight into the impact of IBD or a specific treatment on distress levels, and reveal the extent of 
distress amongst this population. Alleviating IBD-distress has the potential to improve patient QoL and 
improve their clinical outcomes.  
 
 
Psychological therapies have been shown to be beneficial for disease-related distress in cancer 61-64, and 
have been used for psychological distress (anxiety and/or depression) in IBD 65, although evidence for the 
latter is conflicting 66 and therapies were not used specifically for disease-related distress. In diabetes, 
interventions addressing psychological and education needs, delivered by the clinical disease specialist 
team rather than by psychology specialists, are most effective 8. Evidence of the relationship between 
distress, clinical outcomes, self-management behaviors, and therapeutic interventions could support the 
introduction and routine availability of psychological / counselling / education support services for IBD 
patients.  
 
Strengths and Limitations  
This study has benefitted from patient (PPI) team involvement which has carried through from our 
preliminary phase 16. PPI engagement and contribution at all stages of project design, delivery and 
reporting strengthens the relevance of the IBD-DS in ensuring it meets and reflects the needs and concerns 
of patients. There has also been considerable qualitative work to generate and reduce items, and these 
developmental processes are reported robustly.  
 
There are also some limitations to consider. Phase1 and 2 participants were recruited from only two tertiary 
care hospitals which receive referrals from a wide geographical area; overall, patients may have a more 
complex disease than those attending regional services, and may also therefore experience higher levels of 
distress. Phase 3 participants were recruited from a single IBD charity whose membership profile is 
predominantly middle-income, white female. Social class, with its relationship to education, may influence 
ability to access social support, and thus mitigate disease-related distress to some extent. The overall 
sample includes a higher proportion of women, and of patients with CD, and thus may not be 
representative of the wider IBD population. Conversely, this may suggest that distress is associated more 
with CD than with UC, prompting those with CD to participate. Although Asian and Afro-Caribbean groups 
were represented, the majority of participants were Caucasian. 
 
We only had self-reported disease activity scores on which to assess if IBD was in remission or relapse. 
Disease scores are known not to be highly correlated with objective measures of inflammation 67, so our 
definition of “stable disease” between test and retest is possibly open to inaccuracy. Further, the low cut off 
point for remission (≤ 4) excludes patients who are clinically in remission but score ≥5 due to permanent 
extra-intestinal manifestations. Finally, the amendment to the DDS (using the acronym ‘IBD’ in place of the 
word ‘diabetes’) was not tested for validity prior to use. 
 
Conclusion 
The 28-item IBD-DS has face and content validity with people with IBD. During refinement it has performed 
well alongside existing validated measures of disease-specific (diabetes) distress and symptoms of anxiety 
and depression. The IBD-DS offers a useful clinical and research tool for assessing IBD-distress. Further 
testing, to include responsiveness to change and determining cut-off points is needed.   
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Figure 1: Flow chart of stages of development of the Inflammatory Bowel Disease Distress Scale 
(IBD-DS)  
*PPI = Patient & Public Involvement;  
 
 
 
DETERMINING 
CONSTRUCT 
VALIDITY & 
RELIABILITY 
ANALYSIS & 
FURTHER ITEM 
REDUCTION 
3 rounds of individual cognitive interviews (n=15) ESTABLISHING FACE 
& CONTENT VALIDITY 
88 items  
Team meeting (all authors and PPI* team).  
Review of cognitive interviewees’ responses: 
1. Removal of items attracting low / zero response (n=24) 
2. 15 similar items combined to create 6 new items (net loss = 9) 
3. New supplementary items (overall distress score, disease 
activity assessment, free text most distressing items) added (n=3)   
58 items: 
55 +3 
supplementary INITIAL ITEM 
REDUCTION 
Review & verification of amendments via cognitive interviews 
(n=3) 
Test (n=168) and retest (n=136) of the draft IBD-DS  
Analysis: complete sets of paired data (n=94)  
Item reduction: 27 items removed:  
1. Removal of items scored as zero by ≥ 65% of respondents  
2. Removal of remaining items scored by < 50% of respondents  
3. Combining highly correlated items  
4. Removal of items with kappa value ≤ 0.60  
 
Secondary analysis of existing data to identify items  
for the draft distress scale (IBD-DS)   
 
94 items Preliminary work (16) 
ITEM GENERATION 
31 items: 
28 scored +3 
supplementary 
POST ITEM 
REDUCTION 
REVIEW 
IBD-DS reviewed again by retest participants (n=12) 
Final IBD-DS: 31 items  
(28 scored + 3 supplementary) 
FINAL VERSION 
CONFIRMED 
CONFIRMING  
CONSTRUCT VALIDITY 
& RELIABILITY 
Second test (n=123) and retest (n=95) of the final IBD-DS  
No further item 
reduction 
indicated 
REPEAT ANALYSIS  Analysis of complete sets of paired data  
in people with stable IBD (n=72)  
A 
B 
C 
D
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E
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F
A 
G
A 
H
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I
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 Sex   
 (n; %) 
Age   
range (mean) 
Ethnic group 
(n; %) 
Diagnosis    n (% of total 
participants) 
Disease activity  HBI or SCCAI; Remission ≤ 4; relapse = ≥5   
(n; % of participants per diagnosis) 
Phase 1 
n=18 
female 
(12;66.6%) 
24-67  
(40.4 years) 
Data not collected Crohn’s disease (14; 77.7%) 
Ulcerative colitis (4; 22.2%) 
Not recorded 
Phase 2 
(test) 
n=168 
 
female  
(92; 54%) 
18-88  
(40.7 years) 
Afro-Caribbean (5; 2.9%) 
Asian (14; 8.3%) 
Caucasian (149; 88.7%) 
Crohn’s disease (105; 62.5%) 
Ulcerative colitis (58; 34.5%) 
IBD Unclassified (4; 2.4%) 
Missing (1; 0.6%) 
CD remission (59; 56%); relapse (40; 38%); missing (6; 5%) 
UC remission (38; 66%); relapse (20; 34%); missing (0; 0%) 
IBDU remission (2; 50%); relapse (2; 50%); missing (0; 0%) 
Phase 2 
(retest) 
n=136 
female  
(71; 52%)  
18-88  
(41.2 years) 
Afro-Caribbean (3; 2.2%) 
Asian (13; 9.5%) 
Caucasian (88.2%) 
Crohn’s disease (88; 65%) 
Ulcerative colitis (44; 32%) 
IBD Unclassified (4; 3%) 
Missing (0; 0%) 
CD remission (53; 60 %); relapse (34; 38.9%); missing (1; 1.1%) 
UC remission (31; 70.5%); relapse (12; 27.3%); missing (1; 2.2%) 
IBDU remission (2; 50%); relapse (2; 50%); missing (0; 0%) 
 
Phase 3 
(test) 
n=123 
female  
(98; 79%) 
17-64  
(35.7 years)  
Afro-Caribbean (2; 1.6%) 
Asian (9; 7.3%) 
Caucasian (112; 91.1%) 
Crohn’s disease (62; 50.4%) 
Ulcerative colitis (58; 47.1%) 
IBD Unclassified (3; 2.5%) 
CD remission (21; 33.9%); relapse (41; 66.1%); missing (0; 0%) 
UC remission (25; 43.1%); relapse (32; 55.2%); missing (1; 1.7%) 
IBDU remission (0; 0%); relapse (3; 100 %); missing (0; 0%) 
 
Phase 3 
(retest) 
n=95 
 
female 
(76; 80%) 
17-64 
(35.3 years) 
Afro-Caribbean (1; 1.05%) 
Asian (7; 7.3%) 
Caucasian (87; 91.65%) 
Crohn’s disease (52; 54.7%) 
Ulcerative colitis (41; 43.2%) 
IBD Unclassified (2; 2.1%) 
 
CD remission (21; 40.3%); relapse (31; 59.7%); missing (0; 0%) 
UC remission (27; 65.8%); relapse (13; 31.7%); missing (1; 2.4%) 
IBDU remission (0; 0%); relapse (2; 100 %); missing (0; 0%) 
 
 
Table 1: Demographic details of study participants   
CD = Crohn’s Disease or Crohn’s Colitis; HBI = Harvey Bradshaw Index; IBDU = Inflammatory Bowel Disease-Unclassified; SCCAI = Simple Clinical Colitis 
Activity Index; UC = ulcerative colitis or proctitis.  
 
 
 Variable 1 Variable 2 N Correlation Coefficient P-value 
     
Phase 2     
     
IBD-DS    HADS anxiety 138 0.64 <0.001 
     
    HADS depression 136 0.54 <0.001 
     
    DDS 131 0.85 <0.001 
     
Phase 3     
     
IBD-DS    HADS Anxiety 121 0.68 <0.001 
     
    HADS Depression 121 0.62 <0.001 
     
   Self-reported  
  distress 
122 0.77 <0.001 
     
Self-reported     HBI 62 0.70 <0.001 
disease activity    SCCAI 62 0.70 <0.001 
     
 
 
Table 2: Data summaries showing correlations between the IBD-DS, the HADS and the DDS, and between self-reported disease activity 
and formal disease activity scores.   
DDS = Diabetes Distress Scale; HADS = Hospital Anxiety and Depression Scale; HBI = Harvey Bradshaw Index; SCCAI – Simple Clinical Colitis 
Activity Index.  
 
 
 
 
 
  Test data Retest data 
Scale N Mean (SD) or 
Median [IQR] 
N Mean (SD) or 
Median [IQR] 
     
HBI 62 5 [2, 7] 52 4 [2, 6] 
SCCAI 60 6 [3, 9] 42 5 [2, 7] 
     
HADS anxiety 122 9.9 (4.5)  - 
HADS depression 122 6.5 (4.2)  - 
     
IBD Distress scale 122 100 (36) 94 98 (37) 
     
 
Table 3: Summary of Phase 3 test and retest data  
HADS = Hospital Anxiety and Depression Scale; HBI = Harvey Bradshaw Index; SCCAI – Simple Clinical Colitis Activity Index.  
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Online DSF 1:  Graphical illustrations of the associations between each of the variables (HADS 
Anxiety, HADS Depression, and DDS) with the IBD-DS score  
DDS = Diabetes Distress Scale; HADS = Hospital Anxiety and Depression Score 
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Please think about how your IBD has been making you feel during the last three months, and whether the 
issues listed below cause you distress. IBD distress means ‘emotional burden or suffering’. Please read each 
statement carefully and tick ‘Yes’ or ‘No’ in the relevant column. If your answer is ‘Yes’, please then circle the 
appropriate response on the scale to indicate how distressing the issue is for you. If a question is not 
applicable to you, please enter a tick in the ‘No’ column.     
  
  
If yes, how distressing is this? 
 I am distressed because ... Yes No 
Mildly                                         Highly 
distressing                         distressing 
1 ... I feel embarrassed by the symptoms of my IBD   1 2 3 4 5 6 
2 
... I may need a temporary or permanent stoma, or other    
    surgery for my IBD 
  1 2 3 4 5 6 
3 
... I worry about how the disease will progress and how this  
    will affect me 
  1 2 3 4 5 6 
4 
... I sometimes do not have access to IBD health    
    professionals when I need it  
  1 2 3 4 5 6 
5 
... some of the health professionals I see don’t always take     
    my concerns seriously enough 
  1 2 3 4 5 6 
6 
... I worry that the treatment I am having for my IBD will not  
    work 
  1 2 3 4 5 6 
7 
... I worry that my IBD treatment will cause unpleasant  
    side-effects 
  1 2 3 4 5 6 
8 ... I feel that the symptoms of IBD are difficult to cope with   1 2 3 4 5 6 
9 ... I worry that there is no cure for IBD   1 2 3 4 5 6 
10 ... I feel that IBD has reduced my opportunities in life   1 2 3 4 5 6 
11 
... it is difficult to talk to my employer, work colleagues or  
    fellow students about my IBD 
  1 2 3 4 5 6 
12 
... I worry about how I will cope financially if I am unable to  
    work 
  1 2 3 4 5 6 
13 
... I worry about the future (planning for a career or ongoing  
    education) 
  1 2 3 4 5 6 
14 
... I worry about how other people will react if they find out I  
    have IBD 
  1 2 3 4 5 6 
15 
... IBD takes up too much of my energy every day and can  
    be overwhelming 
  1 2 3 4 5 6 
16 
... IBD controls my life and prevents me from doing the  
    things I want to do 
  1 2 3 4 5 6 
17 
... I find the uncertainty of the disease and its potential to  
    disrupt important events, difficult at times  
  1 2 3 4 5 6 
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If yes, how distressing is this? 
 I am distressed because ... Yes No 
Mildly                                         Highly 
distressing                         distressing 
18 
... I worry that when I am stressed about IBD, I make my  
   symptoms worse 
  1 2 3 4 5 6 
19 
... I feel that IBD prevents me from being the person I want  
    to be 
  1 2 3 4 5 6 
20 
... I feel that IBD negatively affects my intimate  
    relationships 
  1 2 3 4 5 6 
21 
... I feel fatigued, unable to think straight and unable to  
    motivate myself much of the time due to IBD 
  1 2 3 4 5 6 
22 
... I feel that other people sometimes do not understand I  
    am unwell 
  1 2 3 4 5 6 
23 ... I worry that any children of mine might develop IBD   1 2 3 4 5 6 
24 ... social situations can be uncomfortable due to my IBD   1 2 3 4 5 6 
25 
... I feel that my IBD sometimes causes me to let other  
    people down 
  1 2 3 4 5 6 
26 ... I often feel concerned about food and eating   1 2 3 4 5 6 
27 
... whenever I leave the house, I worry about finding or  
    needing the toilet, having a bowel accident or passing  
    loud or smelly wind 
  1 2 3 4 5 6 
28 
... when I am in crowded public places I do not feel in      
    control  
  1 2 3 4 5 6 
 
29 
On a scale of 0 to 6, where 0 is ‘Not distressed’ and 6 is ‘Highly distressed’, how would you rate your 
current level of distress? Please circle one option 
0 1 2 3 4 5 6 
Not 
distressed 
Highly  
distressed 
 
30 
Please indicate your current level of disease activity: 
Please circle one option   
In remission Mild flare Moderate flare Severe flare 
 
Finally, please identify the issue(s) causing you the most distress at the moment, and write them in the 
box below ....  
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